Your shopping cart is currently empty

EGFR kinase inhibitor 6 (Compound 4b) is an orally active epidermal growth factor receptor (EGFR) kinase inhibitor with an IC50 of 24.34 μM. It induces apoptosis and demonstrates anticancer and anti-inflammatory properties, exhibiting low toxicity with an LD50 range of 500-2000 mg/kg.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | EGFR kinase inhibitor 6 (Compound 4b) is an orally active epidermal growth factor receptor (EGFR) kinase inhibitor with an IC50 of 24.34 μM. It induces apoptosis and demonstrates anticancer and anti-inflammatory properties, exhibiting low toxicity with an LD50 range of 500-2000 mg/kg. |
| In vitro | EGFR kinase inhibitor 5 (0-80 μM, 72 h) hinders the migration of A549 cancer cells and reduces the viability of A549, MCF7, and HCT116 cancer cells, with IC₅₀ values of 21.06, 29.25, and >60 μM, respectively. |
| In vivo | The kinase inhibitor EGFR 6 (13.37 mg/kg, oral, 15 days) demonstrates anti-inflammatory activity in a carrageenan-induced rat paw edema model while showing a low propensity to cause ulceration and lipid peroxidation. |
| Formula | C21H16ClN3OS2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.